SCHEMBL6465540

SCHEMBL6465540

COc1cc(-c2cn(C3CCOCC3)c3ncnc(N)c23)ccc1NC(=O)CCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 6/20 0.59
LCK P06239 6/20 0.59
TEK Q02763 5/20 0.59
HCK P08631 2/20 0.55
RIPK2 O43353 4/20 0.51
ABL1 P00519 3/20 0.49
EGFR P00533 3/20 0.49
ABL2 P42684 3/20 0.49
EIF2AK3 Q9NZJ5 3/20 0.49
KDR P35968 2/20 0.49
NEK7 Q8TDX7 2/20 0.48
IGF1R P08069 1/20 0.48
FLT3 P36888 2/20 0.48
FYN P06241 1/20 0.48
RET P07949 1/20 0.48
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48
LTK P29376 1/20 0.48
MAP2K2 P36507 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861366 0.91 SRC (0.59) SRCLCKTEKHCKRIPK2
SCHEMBL6458940 0.89 TEK (0.76) SRCLCKTEKHCKRIPK2
SCHEMBL6463636 0.89 TEK (0.76) SRCLCKTEKHCKRIPK2
SCHEMBL6458946 0.89 TEK (0.76) SRCLCKTEKHCKRIPK2
SCHEMBL6461905 0.88 LCK (0.59) SRCLCKTEKHCKRIPK2
SCHEMBL6861029 0.87 LCK (0.59) SRCLCKTEKHCKRIPK2
SCHEMBL6460272 0.86 SRC (0.61) SRCLCKTEKHCKRIPK2
Maleic Acid SCHEMBL27578432 0.86 TEK (0.71) SRCLCKTEKHCKRIPK2
SCHEMBL2074111 0.86 TEK (0.58) SRCLCKTEKRIPK2ABL1
Carbamic Acid SCHEMBL7852916 0.84 SRC (0.60) SRCLCKTEKHCKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 US disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN SRC 46/4885LCK 1/4885TEK 1465/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI SRC 206/4885LCK 6/4885TEK 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.